BigOmics Analytics

Progress records

Stage of your startup

Paying users

When did you start

November 2018

City

Bellinzona, Ticino, Switzerland

Definition in 1 sentence

BigOmics democratises biodata analytics via self-service analytics platforms. We are building the "Tableau" of biodata analytics. Come&join!

Elevator pitch

We are building the "Tableau" of biodata analytics. The traditional way of biodata analytics is a bottleneck: complex, time consuming and expensive. With our self-service analytics platforms, non-technical users (biologists) can easily get insight within minutes. Fast, easy-to-use and affordable!

Are you incorporated?

Yes

Business model

Describe the problem you are solving

Biodata analytics is the bottleneck. Genomics sequencing technologies are revolutionising Healthcare and the field is entering the era of BIG DATA. The bottleneck is quickly shifting away from the availability of genomic data to the analysis of the data: biologists, who need to understand their experimental data, often lack the computational background to effectively use the data and are completely dependent on bioinformatics experts. Furthermore, the amount of biological data is growing faster.

How are your customers solving that problem today?

The traditional way of biodata analysis can be seen as a full-service analysis, where bioinformaticians analyse the data and provide static reports to biologists. This process can easily take up to 1-2 weeks due to redundant analyses, misunderstandings and a lack of intimate knowledge of the biological nature of datasets from bioinformaticians. Alternatively, life scientists can also analyse data on their own. However, it requires learning advanced programming and statistical knowledge.

Target custormers - Define customers, who are they

How do you plan to acquire customers?

We execute a parallel B2C2B marketing strategy, where we use mainly an inbound marketing strategy to reach our self-service customers (Basic and Professional) and an effective outbound marketing strategy, as well as distributors (strategic partners), to reach our Enterprise customers. This strategy helps us to quickly penetrate the market and acquire the first Enterprise customers.

What is your revenue model or expected revenue model?

We follow the Freemium business model by offering a free version of our SSA platforms (Basic subscription) and a paid one (Professional subscription), plus an Enterprise subscription with possible customisation as well as on premise installation and embedment.

Market info

What is your target market?

Next generation genomics technologies are revolutionising healthcare and medicine by generating huge amounts of genomic data that are making unprecedented discoveries and diagnoses possible. The current global biodata analytics market is expected to reach around USD 20 billion by the end of 2023, growing at 21.7% CAGR (BCC Research, 2019).

What is your total available market size

$ 41,000,000,000

What steps have you taken to validate the market?

2019: Internal validation at the Institute (>30 projects).
2019: External paying clients (10 projects, around 10000 USD in revenues).
2020: We launched Basic edition of our platforms (more than 8'000 users)
2020: We signed 4 Enterprise partnerships agreements.

Milestones for 2020:
- Set Professional version by Q3 2020.
- Close our financing round by Q4 2020.
- Generate target revenue of 150000-200000 USD.

Do you have competitors? Please write down the names

Tag.bio

https://tag.bio/

Rosalind

https://www.onramp.bio/

AIR

https://transcriptomics.sequentiabiotech.com/

Competition: write down competitors and explain

Who are your competitors and how are you different?

Our close competitors are Rosalind, tag.bio and AIR. Compared to these platforms, our platforms provide easy access to vast amounts of public data, have strong visualisation, offer advanced analytics, easy to use, rapid and affordable.
❖ Hi-speed analytics. Get instant insight into your data.
❖ Ease of use. Analytics anywhere, anytime.
❖ Interactive visual analytics. See, touch and understand.
❖ Advanced statistical methods.
❖ Access to pre-computed public data.
❖ Affordability.

Traction / KPIs

What progress have you made in the last six months?

We recently published our platforms in two respective journals (Nature Immunology and NARGAB). Due to effective inbound marketing in the past quarter, we've gained a good traction on social media and more than 8'000 users have visited our running platforms. We recently formed four partnerships with companies operating in the primary and secondary analytics markets. BigOmics also got accepted to both the EU-financed InvestHorizon Accelerator and Alchemist - a Silicon Valley-based accelerator.

How many customers/users do you currently have?

Our platforms have been used in more than 30 internal projects at the Institute and in more than 10 projects of paying customers. In addition, more than 8'000 users have visited our running platforms.

What is your monthly growth rate?

The average monthly growth of our platforms' user base is 32% (min 20% and max 46%). The cumulative user base of the Basic editions since the platforms were launched in 2020 are: March: 1633 April: 3036 May: 4292 June: 5353 July: 8123

Describe traction

Finance

How much runway do you have left(Month)?

How is equity divided?

Co-Founder

Murodzhon Akhmedov

[email protected]

Co-Founder

Ivo Kwee

[email protected]

Employee stock option

Team

[email protected]

Venture Investor

Alchemist Accelerator

[email protected]

How much money raised since start?

$ 375,000

Revenue lifetime

$ 1,000

Last months revenue

$ 2,000

Investment round

Target fund to raise

$ 1,500,000

Equity on offer

% 25

Number of employees

Other info Write bullet points (Grants, prizes, acceleration)

Add more comments

Owner member

Yes

Member role

Co-founder

Name surname

Murodzhon Akhmedov

Title

CEO

Education

Doctorate Degree

School name

USI/MIT

Birthdate

01 August 1988

City

Bellinzona, Ticino, Switzerland

Short Bio

Murodzhon Akhmedov. CEO, co-founder.
PhD in Informatics, specialised in biodata analytics.
BSc in Management. Expert on graph algorithms in biology.

Meeting story with Cofounders

I met Dr. Ivo Kwee during my PhD. Actually he was a co-supervisor of my PhD program. Dr. Kwee has over ten years of experience in bioinformatics and is an expert in omics integration. Prior to establishing the startup, Dr. Kwee worked as a head of Bioinformatics unit at the Institute of Oncology Research (ior.iosi.ch) and the Institute for Research in Biomedicine (irb.usi.ch) with more than 15 years of experience.

Working together time

As co-founders, me and Ivo, have been working for quite long, almost for 7 years. While working closely with biologists in the lab during my PhD, we realised that biologist are pretty much separated from their data due to the lack of technical background. With our self-service analytics platforms, we bring biologists closer to their data, enable them to visualise and explore their data on their own.

Owner member

Member role

Co-founder

Name surname

Ivo Kwee

Title

CTO

Education

Doctorate Degree

School name

University College London, U. of London

Birthdate

01 January 1979

City

Bellinzona, Ticino, Switzerland

Short Bio

Dr. Ivo Kwee (CTO), received a MEng from the Hokkaido University (Japan), and his PhD in Medical Physics from the University College London (UK). He continued for a postdoc at Dalle Molle Institute of Artificial Intelligence (IDSIA, Switzerland) and worked at the Institute of Oncology Research (IOR)

Owner member

Member role

Employee

Name surname

Axel Martinelli

Title

CSO

Short Bio

PhD in Biology. MSc in Immunology and Bioinformatics. Expert on parasitology and malariology.

Owner member

Member role

Employee

Name surname

Martina Drinjak

Title

CBO

Short Bio

Master student in Marketing & Transformative Economy (USI), with a specialisation in Customer Experience and Value.

Executive